Rhodiola Rosea for Mental and Physical Fatigue
|ClinicalTrials.gov Identifier: NCT01278992|
Recruitment Status : Unknown
Verified February 2011 by Government of Alberta.
Recruitment status was: Enrolling by invitation
First Posted : January 19, 2011
Last Update Posted : February 15, 2011
|Condition or disease||Intervention/treatment||Phase|
|Fatigue||Dietary Supplement: Rhodiola rosea||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized Trial of Rhodiola Rosea for Mental and Physical Fatigue in Nurses|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||April 2011|
|Estimated Study Completion Date :||April 2011|
Dietary Supplement: Rhodiola rosea
- Fatigue [ Time Frame: 42 days ]
A vitality subscale of the generic health-related quality of life instrument, RAND-36, will be employed to assess fatigue.
A Visual Analogue Scale for Fatigue (VAS-F) will be concurrently administered to assess fatigue and compare to the RAND-36 fatigue assessment.
- Health-related quality of life [ Time Frame: 42 days ]The health-related quality of life, RAND-36 will also assess physical functioning, role limitations caused by physical health problems, role limitations caused by emotional problems, social function, emotional well-being,and general health perceptions
- Individualized Outcomes [ Time Frame: 42 days ]Measure Yourself Medical Outcomes Profiles to measure change in items of importance to the participant, as identified by the participant.
- Adaptive Capacity [ Time Frame: 42 days ]Adaptive Capacity Index - 21 item questionnaire to measure a subject's ability to adapt to stressors
- Adverse Event Monitoring [ Time Frame: 42 days ]number of patients with any untoward medical occurance as a measure of safety
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01278992
|University of Alberta|
|Edmonton, Alberta, Canada, T6G 2E1|
|Principal Investigator:||Sunita Vohra, MD FRCPC MSc||University of Alberta|